MedTrace Logo

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

NCT05232175 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteers

Conditions

  • Health, Subjective

Interventions

DRUG

ALT-BB4

Recombinant Hyaluronidase

DRUG

0.9%NaCl

Normal Saline

Sponsors & Collaborators

  • Alteogen, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2022-08-24
Completion
2022-08-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05232175 on ClinicalTrials.gov